On the Brink of Generic Biotech Drugs, What’s the Cost to Innovation?

In a recently published report, the Federal Trade Commission suggested that the current allotment of a 12- to 14-year regulatory exclusivity period for product innovation to develop products at biotech companies is“too long to promote innovation.”
The same report, published June 4, also indicated that developing generic biotech drugs would help bring down the cost [...]

The Cost of US Healthcare: Could Private Equity be an Answer?

It is common knowledge that the global economy has been irreversibly changed since last Summer. Now nearly two years into serious recession, the United States has scrambled to hold any sort of ground in consumer confidence, losing countless jobs and huge revenues in almost every sector. Real estate and retail have been hit especially hard, [...]

Conducting clinical trials cost effective to register pharmaceutical product for sale in europian contries

Almost every pharmaceutical company in world often look at other countries like Africa, Asia, Latin America and Eastern Europe in an attempt to further enhancing pharmaceutical business and revenue and growth hence to conduct clinical trials that are, by comparison, much more cost effective. The attraction of these emerging markets is recognized by many in [...]